... Conjugated peptides or recombinant proteins are u...uce antibodies in 2 rabbits. pre-immune and three...until the titer reaches 1:4,000 Western blot anal...rification Antibodies are eluted using both pH11 ...
Sheep Anti-Human IDO Monoclonal Antibody, Clone ZMD.420 from Invitrogen
ARCA (Anti Reverse Cap Analog) from Ambion
Rabbit anti-UBAP2L/NICE4 AbVantage Pack Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Biology Products:(Date:11/24/2009)..., DUBLIN,November24/PRNewswire-FirstCall/--Sh...biopharmaceuticalcompany,today,announcedthatithass...ucerasealfa,thecompany,senzymereplacementtherapyin...hisisthethirdmarketing,applicationforvelaglucerase...ntheUnitedStatesandCanada. , Basedonaglobalsu...
(Date:11/24/2009)... Program Connects Customer...amples Collected with DNA Genotek Products , ..., 2009 -- DNA Genotek , a leading provider of pro...ion and preparation, today announced its new globa...enhancements for DNA Genotek,s partner community a...
(Date:11/23/2009)... CHAMPAIGN, Ill. You can think of it as origami ...ersity of Illinois have developed a technique for ...silicon structures from thin films by coupling pho... capillary interactions. , The films, only a few ...s not possible with thicker pieces of the same mat...
(Date:11/23/2009)..., MISSISSAUGA,ON,Nov.23/PRNewswire-FirstCall/...encesproductdevelopmentcompanythatidentifiesandadv...ductsatvariousstagesofdevelopment,todayreportedtha...ItrialevaluatingCYT387,apotent,orally-administered...linicinRochester,Minnesota.AproposaltomergeCytopia...
Breaking Biology Technology:Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Water droplets direct self-assembly process in thin-film materials 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4